Special Issue "Impact of Nanobiotechnology (Nanomedicine) on the Future of Medicine: The Road toward Precision Medicine 2.0"
Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 8795
2. Vascular Vision Pharmaceuticals Co., Rensselaer Polytechnic Park, Troy, NY 12180 USA
Interests: pharmaceuticals; biopharmaceuticals and diagnostics; nanomedicine; cardiovascular diseases; neurological disorders; hematology and oncology; biosimilar and nanosimilar; angiogenesis; inflammation; thrombosis; integrin and cell adhesion molecules; target identification; molecular mechanisms and signaling pathways; preclinical; clinical; marketing and post marketing studies; regulatory and ethical issues
Special Issues, Collections and Topics in MDPI journals
Special Issue in Cancers: Cancer Cell Imaging
Special Issue in International Journal of Molecular Sciences: Vascular Biology and Therapeutics
Special Issue in Biomedicines: Anti-Angiogenesis Therapeutics in Cancer
Special Issue in Biomedicines: Impact of Nanobiotechnology (Nanomedicine) on the Future of Medicine: The Road toward Precision Medicine
Special Issue in Biomedicines: Transition from Nutraceuticals to Nano-Nutraceuticals and Nano-Pharmaceuticals: Impact on Health and Diseases
Special Issue in Biomedicines: Selected Papers in the 1st International Electronic Conference on Biomedicine (ECB 2021)
Special Issue in Biomedicines: Anti-angiogenesis Therapeutics in Cancer, Ocular and Skin Disorders
Special Issue in Biomedicines: Biomedicines: 10th Anniversary
Special Issue in Biomedicines: Selected Papers in the 2nd International Electronic Conference on Biomedicines (ECB 2023)
Topical Collection in Biomedicines: Advanced Biomedical Science and Technology
Evidence from the scientific and medical communities has demonstrated the potential impact of nanotechnology/biotechnology and nanomedicine on the improved management of cancer and other disorders, in terms of early diagnosis and targeted therapy, leading to significant progress in accelerating precision medicine applications. The utilization of nanobiotechnology for the development of novel targeted nanocarrier systems has the potential to offer improved biomedicine (small molecule, peptide, and genes) delivery through improved pharmacokinetics, pharmacodynamics, and safety profiles. Targeted delivery of drug-incorporated nanoparticles, through conjugation of tumor-specific cell surface markers, such as tumor-specific antibodies or ligands, could enhance the efficacy and safety of anticancer drugs. Additionally, multifunctional characteristics of the nanocarrier system would allow for simultaneous imaging of various types of cancers/microenvironments and targeted drug delivery (therapeutics) along with monitoring (theranostics).
The scope of this Special Issue is to cover recent progress in nanotechnology/biotechnology as it relates to nanomedicine, targeted delivery of medicines and biomedicines, and diagnostics. A key aim is to present the latest advances in various nanomedicine approaches for the detection and treatment of various types of organ-specific diseases, vascular targeting, vaccine development, and the overall impact of nanomedicine on advancing precision medicine. Additionally, this Special Issue aims to cover nanonutraceuticals, nanocosmetics using a single or a combination of various bioactive compounds derived from natural products, and impacts on disease prevention.
Prof. Dr. Shaker Mousa
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- precision medicine
- disease prevention
- early detection